The FDA has sent warning letters to companies selling compounded tirzepatide and semaglutide ... approved tirzepatide on its own (as a genereic unbranded prescriptio) for weight loss or the ...

Patients with obesity who took semaglutide had lower risk for fractures vs. those who had sleeve gastrectomy. More research is needed to determine the relationship between semaglutide and bone health.

A specific group of nerve cells in the brain stem appears to control how semaglutide affects appetite and weight – without causing nausea. The discovery, made at the University of Gothenburg, could ...

The combination study is designed to evaluate the safety and preliminary efficacy of a single-dose of ultra-long-acting subcutaneously administered ASC47 in combination with four doses of semaglutide ...

A specific group of nerve cells in the brain stem appears to control how semaglutide affects appetite and weight – without causing nausea. The discovery, made at the University of Gothenburg ...

PLAINSBORO, N.J., May 22, 2025 /PRNewswire/ -- Today, as the US Food and Drug Administration (FDA) grace period for mass compounding of "semaglutide" expires, Novo Nordisk announced a series of ...

Veru's Phase 2b study shows enobosarm combined with semaglutide improves safety, reduces gastrointestinal issues, and promotes fat loss while preserving lean mass. There is a potential risk that ...

Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY ...

Starting in 2022, increased demand led to shortages of semaglutide injections sold by Novo Nordisk under the brand names Ozempic and Wegovy, as well as tirzepatide injections Zepbound and Mounjaro ...

3️⃣ Semaglutide crackdown: Shortages of Ozempic and other GLP-1 drugs for weight loss and diabetes allowed pharmacies to sell off-brand products not approved by the US Food and Drug ...

Combining semaglutide with muscle-preserving antibodies protected lean mass – sparing approximately 50%-80% of the lean mass lost with semaglutide alone – while also increasing loss of fat ...

In a head-to-head diet-induced obese (DIO) mouse model, low dose ASC47 in combination with semaglutide demonstrated a 56.7% greater reduction in body weight with muscle preservation compared to ...